Stories
Anupam Rasayan Targets Double Revenue for Bliss GVS Pharma in Three Years
C
CNBC TV18•30-09-2026, 11:50
Anupam Rasayan Targets Double Revenue for Bliss GVS Pharma in Three Years
- •Anupam Rasayan aims to double Bliss GVS Pharma's revenue to ₹2,000 crore within two to three years, up from ₹927 crore in FY26.
- •The acquisition will integrate Anupam Rasayan's key starting materials with Bliss GVS's finished dosage formulations, creating an integrated pharmaceutical platform.
- •Strategies to achieve this goal include doubling plant utilization to 60-70%, expanding into new markets beyond Africa, and growing contract manufacturing.
- •This target would significantly boost Anupam Rasayan's topline, nearly matching its ₹2,383 crore revenue in FY26.
- •Bliss GVS shares have tripled in six months anticipating the acquisition, while Anupam Rasayan shares have declined by nearly 8%.
Key Questions Answered
Anupam Rasayan aims for Bliss GVS Pharma to reach a revenue of ₹2,000 crore over the next two to three years, nearly doubling its FY26 revenue of ₹927 crore.
According to Deputy CFO Vishal Thakkar, the growth will be driven by doubling plant utilisation to 60-70%, expanding contract manufacturing, and entering new markets outside Africa.
The acquisition allows Anupam Rasayan to build an integrated pharmaceutical platform by combining its key starting materials business with Bliss GVS's finished dosage formulations.
